Global Reports

2026 Global Trade Outlook: How 6,000 corporates are re-engineering supply chains and managing rising payment risks

Despite intense trade tensions and multiple layers of risks, Allianz Trade upgrades 36 country risk ratings for only 14 downgrades.

Pharma growth accelerates with aging populations, rising chronic diseases, biosimilar competition, and AI-driven drug discovery transforming the industry.

Global GDP growth remains strong... for now. It is expected to reach +2.9% in 2026 and +2.8% in 2027, following a robust +3% in 2025.

Allianz Research forecasts global business insolvencies to rise +6% in 2025, and +5% in 2026, reaching record highs. Explore the global insolvency outlook for 2026-27, including the risks from low growth, persistent financing cost and sector fragilities.

US tariffs are reshaping supply chains, prompting retaliation and heightening uncertainty. Companies will continue to adapt as the trade war is here to stay.

Explore the latest trends in Days Sales Outstanding and Working Capital Requirements. Discover how rising DSO impacts your business and why proactive risk management is crucial in today’s volatile market.

Explore 2025 global trade, uncovering the impacts of trade wars and deals on global companies. Learn how firms navigate geopolitical tensions, focusing on US-China relations and emerging opportunities in Europe and Latin America.

Explore key 2025 trends in the Asia-Pacific chemicals sector, from industrial growth and sustainability to diversified supply chains shaped by post-COVID and geopolitical shifts.